suppression among CRF01_AE-infected patients than among those infected with subtype D or A [6] .
To address the paucity of such studies in non-Western settings, we examined this issue in Singapore, a setting with universal access to healthcare and cocirculation of subtypes. Prior studies from Thailand and Singapore suggest that treatment-naive subjects infected with a non-B subtype ( predominantly CRF01_ AE) experience faster immunologic decline than do subtype B-infected subjects [7] [8] [9] . The impact of this difference on subsequent immunologic recovery after ART remains unknown.
We performed a retrospective analysis of treatment-naive subjects recruited from February 2008 to August 2009 at the Communicable Disease Centre, the national HIV referral center. Inclusion criteria included CD4 cell counts ≤3 months before and 9-15 months after treatment initiation. Subtype assignment was based on sequencing of the protease, gp120, and gp41 regions, as described elsewhere [10] .
Seventy subjects (73.7%) were infected with non-B subtypes (62 CRF01_AE, 8 CRF51_01B). Among subtype B-infected subjects, the proportions of men who have sex with men (60.0%) and non-Chinese subjects (28.0%) were significantly higher than in non-B-infected subjects (37.1% and 4.3%, respectively).
At presentation for care, the median CD4 cell counts for subtype B-infected and non-B-infected subjects were 257 and 202 cells/mm 3 , respectively (P = .05) ( Table 1 ). The median time from clinical presentation to ART initiation was 186 days for subtype B-infected subjects, and 54 days for non-B-infected subjects. Median pre-ART CD4 cell counts were 237 cells/mm 3 the non-B group; P = .009).
In an Asian setting involving predominantly ethnically Chinese subjects, non-B-infected subjects had lower CD4 cell counts 9-15 months after ART initiation than did subtype B-infected subjects. It is likely that lower CD4 cell count at treatment initiation among non-Binfected subjects contributes to poorer immunologic recovery. In fact, nadir pretreatment CD4 cell count has been a strong predictor of immunologic recovery after ART [11] . Because few subjects (27.4%) had available HIV loads, we could not analyze the rates of virologic suppression between subtypes.
Our results suggest that poorer immunologic status among non-B-infected subjects in Singapore negatively affects immunologic recovery. Further studies 
